JDJanet DuBois

Janet DuBois

*This is an algorithmically generated author record based on publicly available information.

Janet DuBois has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary

    by Andrew Blauvelt, Zoe D. Draelos, Linda Stein Gold, Javier Alonso-Llamazares, Neal Bhatia, Janet DuBois, Seth B. Forman, Melinda Gooderham, Lawrence Green, Scott T. Guenthner, et al.


  • Open Access

    Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks

    by Andrew F. Alexis, Michael Bukhalo, Fran E. Cook-Bolden, James Q. Del Rosso, Zoe D. Draelos, Janet C. DuBois, Laura K. Ferris, Seth B. Forman, Steven E. Kempers, Leon H. Kircik, et al.

    Background The efficacy and safety of once-daily roflumilast foam 0.3%, a potent phosphodiesterase 4 inhibitor, has been demonstrated in patients with seborrheic dermatitis (SD). Objectives To evaluate long-term effects of roflumilast foam 0.3% in patients with SD. Methods A phase II, open-label trial (no. NCT04445987) was conducted in patients (aged ≥ 12 years) with SD who completed a prior roflumilast foam trial or were naïve to roflumilast and vehicle. Patients applied roflumilast foam 0.3% once daily to all affected areas, including the scalp, face, trunk, and intertriginous areas, for 24 or 52 weeks (during the course of the trial, the protocol was amended to extend the duration of treatment from 24 weeks to 52 weeks). The primary endpoints were occurrence of treatment-emergent adverse events (AEs); local tolerability and efficacy (via Investigator Global Assessment [IGA]) were also assessed. Results Overall, 400 patients participated, among whom 62 were enrolled for 52 weeks. AE rates were low, and ≤ 1.1% reported stinging sensation at the application site at each visit. Durable improvement in signs and symptoms of SD was observed at weeks 24 and 52, with 76.0% and 80.4% of patients, respectively, achieving an IGA of clear or almost clear. Conclusions Roflumilast foam 0.3% was well tolerated and improved and/or maintained improvements in signs and symptoms of SD for up to 52 weeks. ClinicalTrials.gov Listing NCT04445987.


  • Open Access

    Safety, Tolerability and Efficacy of Tirbanibulin Ointment 1% Treatment on 100 cm2 of the Face and Scalp in Patients with Actinic Keratosis: A Phase 3 Study

    by Neal Bhatia, Andrew Blauvelt, Edward Lain, Abel Jarell, Janet DuBois, Maria Luisa Tamarit, Meritxell Falqués, Vera Kiyasova, Laura Padullés, Raquel Otero

    Introduction: Tirbanibulin ointment 1% has demonstrated efficacy, tolerability, and safety for AK and is approved in the US and Europe for treating AK on the face or scalp over an area up to 25 cm2 [1]. The objective of this study was to evaluate safety and tolerability of tirbanibulin applied to a larger area, a field of 100 cm2, on the face or balding scalp in adult patients with AK. Methods: A phase 3, multicenter, open-label, single-arm study (NCT05279131) was conducted among adult patients having a treatment field on the face or balding scalp that measured 100 cm2 and contained 4-12 AKs. Patients received tirbanibulin for 5 consecutive days and were evaluated for safety, tolerability, and AK persistence until Day 57. Safety was assessed by evaluating treatment emergent adverse events (TEAEs). Tolerability endpoints included scores, 0 (absent) to 3 (severe), of 6 local signs captured at each timepoint. Exploratory efficacy was measured as percentage change from baseline (CFB) in AK lesion count. Results: A total of 105 patients (20 sites in the US) were included in the safety analysis set (males: 69%; ≥65 years: 65%; Fitzpatrick skin type II: 63%; AK on the face: 68%). Most common local tolerability signs after 100 cm2 tirbanibulin administration were erythema (96% of patients) and flaking/scaling (85%), which were mild-to-moderate in severity, peaked at Day 5 to 8, and resolved or returned to baseline by Day 29. Severe erythema was reported only in 6% of patients and severe flaking/scaling in 9% of patients. Overall, the tolerability profile of treating a 100 cm2 area was consistent with that seen with a 25 cm2 area [1]. Most frequent TEAEs were application site pruritus (11%) and application site pain (9%), consistent with previous Phase 3 study results. No serious TEAEs related to drug were reported. Maximum local tolerability composite score was 4 out of 18, consistent with prior pivotal trials. Patients entered the study with a mean of 7.7 AKs and completed the study with a mean of 1.8 AKs, indicating outstanding efficacy. Mean percentage CFB in lesion count at Day 57 was 78%, consistent with the Phase 3 study with a 25 cm2 treatment area [1]. Conclusions: Safety, local tolerability, and efficacy in patients with AK treated with tirbanibulin over a 100 cm2 area were consistent with those previously reported in patients with AK treated in pivotal trials with tirbanibulin over a smaller area. [1] Blauvelt A et al. N Engl J Med. 2021;384(6):512–20.


  • Open Access

    Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics

    by John E. Jett, Michael McLaughlin, Mark S. Lee, Lawrence Charles Parish, Janet DuBois, Tooraj Joseph Raoof, Glenn Tabolt, Timothy Wilson, Matthew C. Somerville, Wayne DellaMaestra, et al.

    Background Tapinarof is a novel topical therapeutic aryl hydrocarbon receptor modulating agent in development for the treatment of psoriasis and atopic dermatitis. Objective This multicenter, open-label trial assessed the safety, tolerability, pharmacokinetics (PK), and efficacy of tapinarof cream 1% once daily (QD) under maximal use conditions in extensive plaque psoriasis. Methods Adults with a baseline Physician Global Assessment (PGA) score of ≥ 3 and body surface area (BSA) involvement ≥ 20% received tapinarof cream 1% QD for 29 days. Safety and tolerability assessments included adverse events (AEs) and local tolerability scales. PK parameters were calculated using non-compartmental analysis. Efficacy assessments included change in PGA, Psoriasis Area and Severity Index score, and %BSA affected. Results Twenty-one patients were enrolled. Common AEs were folliculitis, headache, back pain, and pruritus (none led to discontinuation). Tapinarof plasma exposure was low, with the majority of concentrations being below detectable limits. At day 29, 14 patients (73.7%) had a ≥ 1-grade improvement in PGA score and six patients (31.6%) had a ≥ 2-grade improvement; four patients (21.1%) achieved treatment success (PGA 0 or 1 and ≥ 2-grade improvement). Conclusion Tapinarof cream 1% QD was well tolerated, with limited systemic exposure and significant efficacy at 4 weeks in patients with extensive plaque psoriasis. ClinicalTrials.gov Identifier NCT04042103.